Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18279383 | 1.00 | — | — | |
| SCHEMBL23748236 | 0.96 | ALDH1A1 (0.64) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL30338212 | 0.92 | CXCR4 (0.69) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL20523496 | 0.92 | — | — | |
| SCHEMBL27902303 | 0.92 | CXCR4 (0.69) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL472205 | 0.88 | CXCR4 (0.75) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| Piperazine SCHEMBL5730316 | 0.88 | ALDH1A1 (0.61) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| Piperazine SCHEMBL28322579 | 0.84 | CXCR4 (0.67) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL22582300 | 0.84 | CXCR4 (0.67) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL796635 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023137335-A2 | METHODS FOR TREATING CD33-POSITIVE HEMATOLOGICAL MALIGNANCIES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2023-07-20 | — | — | WO | claimed |
| US-20160356796-A1 | IRON (II) ION DETECTION AGENT AND DETECTION METHOD USING THE SAME | METALLOGENICS CO., LTD. (JP) | 2016-12-08 | — | — | US | claimed |
| WO-2023137335-A2 | METHODS FOR TREATING CD33-POSITIVE HEMATOLOGICAL MALIGNANCIES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20110110866-A1 | Elastin-like polypeptide and gadolinium conjugate for magnetic resonance imaging | DUKE UNIVERSITY (US) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110110866-A1 | Elastin-like polypeptide and gadolinium conjugate for magnetic resonance imaging | ELANE, ENPEP, ERMP1 | CXCR4 1908/4885SMN1; SMN2 963/4885ALDH1A1 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.